The U.S. Shakes Up Global Pharma Supply Chains
The Act curbs US-China biotech collaborations, spurring opportunities for emerging markets in pharma supply chains. The Act’s restrictions position Indian CDMOs to gain market share, potentially rivaling China’s industry dominance.
Newsletter
Get Every Weekly Update & Insights
[mc4wp_form id=]